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A B S T R A C T
Background: Depression is highly prevalent among people with MS, and determinants thereof would be useful.
Objectives: We examined the relationship of demographic and clinical factors with positive depression-screen
and change in depression over 2.5 years in people with MS.
Methods: Positive depression-screen assessed by Patient Health Questionnaire (PHQ)-2 and PHQ-9. Associations of
demographic and clinical factors with depression-screen and change thereof assessed using multivariable regres-
sion models, adjusted for age, sex, disability, fatigue, antidepressant use, and baseline PHQ-2, as appropriate.
Results: Overweight/obese BMI, comorbidity number, fatigue, and disability were associated with positive de-
pression-screen, while married/partnered state, being employed, higher perceived socioeconomic status, and
greater education were inversely associated with depression-screen. After adjustment, only marital status, so-
cioeconomic status, antidepressant medication use, and fatigue were associated with risk of newly positive
depression-screen. MS type, relapse number and immunomodulatory medication use were not associated with
depression-screen after controlling for disability and fatigue.
Conclusion: In a large prospective cohort study of depression in people with MS, we substantiated several po-
tential determinants of a positive depression-screen and depression trajectory, particularly fatigue. Given that
fatigue is the most common and most significant clinical symptom for people with MS, efforts to reduce fatigue
may have follow-on benefits for reducing depression.
1. Introduction
Depression is common among people with MS, with estimates ran-
ging from 20–50% in various studies (Koch et al., 2008; Patten et al.,
2017; Wood et al., 2012; Zigmond and Snaith, 1983). Understanding
the characteristics of depression in people living with MS, and parti-
cularly what drives the onset and recovery from depression, is im-
portant in improving their quality of life.
We have previously described the characteristics of screening positive
for depression in this sample at baseline (n=2459)(Taylor et al., 2014),
finding 19.3% screened positive for depression as measured by the Patient
Health Questionnaire (PHQ)-2(Lowe et al., 2005), and that positive de-
pression-screen was more common among participants with higher BMI
and those with greater fatigue and disability, but less common among
those who were partnered, employed or more educated. These results are
similar to those found in an Australian study of participants with estab-
lished MS (n=198) using the Hospital Anxiety and Depression Scale
(HADS) (Zigmond and Snaith, 1983), which found a positive depression-
screen frequency of 18.5% and that positive depression-screen was more
prevalent among those with greater disability and fatigue (Wood et al.,
2012). Similar frequencies of depression have been found early after
symptom onset: in an Australian multicentre cohort of people recruited
soon after symptom onset (n=236), the frequency of positive depression-
screen as measured by HADS was 16.0% (Simpson et al., 2016), greater
disability associated with positive depression-screen. Studies of depression
in MS using other depression screening tools have found similar results
(Brown et al., 2009; Chwastiak et al., 2002; Solaro et al., 2016), with
fatigue the most consistent determinant.
Several longitudinal studies have been undertaken, examining
change in depression over time. Wood and colleagues (n=198) found
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the frequency of positive depression-screen increased by 7.3% per year of
follow-up over 2.3 years, strongly predicted by disability (Wood et al.,
2012). The BEYOND clinical trial (n=891 with depression data) ex-
amined depression using the Beck Depression Inventory-II, finding an
average frequency of positive depression-screen of 25–30%, not greatly
varying over three years of follow-up (Schippling et al., 2016). Koch and
colleagues followed a subgroup of 94/228 patients with baseline de-
pression data for ten years, finding the proportion with clinically sig-
nificant depression as measured by the Center for Epidemiologic Studies
Depression Scale increased from 47.9% to 52.1% (Koch et al., 2008).
While there are many cross-sectional studies examining mood and
depression in MS, there is a comparative lack of prospective studies of
change in depression in large representative samples. We undertook a
prospective cohort study among an international sample of people
living with MS followed over 2.5 years, examining the demographic
and clinical characteristics of positive depression-screen at 2.5-year
review, and of change in depression-screen during follow-up. Of note,
the lifestyle determinants of depression-screen during this same period
are described in another article (Taylor et al., 2018).
2. Methods
2.1. Participants and data collection
Participants were enrolled in the HOLISM study for which metho-
dology has been described previously (Hadgkiss et al., 2013; Weiland
et al., 2018). Participants were recruited via online platforms, and
SurveyMonkey® was used to provide respondents with a participant
information sheet and survey. Inclusion criteria required participants be
≥18 and self-reporting a physician diagnosis of MS. The University of
Melbourne Health Sciences Human Ethics Sub-Committee provided
ethical approval; all participants provided informed consent.
A range of demographic, lifestyle, and clinical parameters were
measured as described previously (Hadgkiss et al., 2013; Weiland et al.,
2018). BMI was estimated from participant-reported height (metres) and
weight (kilograms) using the function, weight/height2. Perceived relative
socioeconomic status (PRSES) was queried as a 9-unit Likert scale, ran-
ging from Poorest to Richest. Disability was assessed using the Patient-
Determined Disease Steps (PDDS) scale (Hohol et al., 1995), from which
the disease-duration-adjusted Patient-derived Multiple Sclerosis Severity
Score (P-MSSS) was calculated (Kister et al., 2013). Fatigue was assessed
using the Fatigue Severity Scale (FSS) (Krupp et al., 1989). Doctor-di-
agnosed relapse number in the preceding year was also queried.
Depression risk was assessed using the PHQ, which has been vali-
dated in MS populations (Marrie et al., 2017), using the two-question
instrument (PHQ-2) (Lowe et al., 2005) at baseline and the nine-ques-
tion instrument (PHQ-9) at follow-up (Kroenke et al., 2001). As the
PHQ-2 is nested within the PHQ-9, we could calculate the PHQ-2 score
at follow-up as well. The PHQ-9 comprises nine questions; participants
are asked to mark the frequency that they have experienced that
symptom in the preceding two weeks, options including “Not at all”,
“Several days”, “More than half the days”, and “Nearly every day”. Note
the asterixed items are those included in the PHQ-2.
1) Little interest or pleasure in doing things*
2) Feeling down, depressed of hopeless*
3) Trouble falling asleep or staying asleep, or sleeping too much
4) Feeling tired or having little energy
5) Poor appetite or overeating
6) Feeling bad about yourself – or that you are a failure or having let
yourself or your family down
7) Trouble concentrating on things, such as reading the newspaper or
watching television
8) Moving or speaking so slowly that other people could have noticed;
or the opposite, being so fidgety or restless that you have been
moving around a lot more than usual
9) Thoughts that you would be better off dead or hurting yourself in
some way.
PHQ responses were scored from 0–3, and these summated. The
PHQ-2 scores ranged 0–6, >2 indicating positive depression-screen.
The PHQ-9 scores ranged 0–27, >9 indicating positive depression-
screen; the PHQ-9 is also subdivided: 5–9 indicating minimal depres-
sion symptoms, 10–14 mild-major depression, 15–19 moderate-major
depression, and 20–27 severe-major depression. Given cell-size con-
straints (n=37 with severe-major depression), the latter two groups
were combined into moderate/severe-major depression.
3. Statistical analysis
Agreement between PHQ-2 and PHQ-9, the latter used as the re-
ference-standard, was assessed by unweighted kappa test (Cohen, 1960).
In addition, sensitivity (true positive/total testing positive) and specifi-
city (true negative/total testing negative) (International Epidemiological
Association, 2001) were calculated.
Log-binomial regression models were used to evaluate factors as-
sociated with positive depression-screen at follow-up and log-multi-
nomial regression models (Blizzard and Hosmer, 2007) used to evaluate
factors associated with PHQ-9 severity, both estimating prevalence
ratios. Multivariable models were adjusted for age, P-MSSS, fatigue,
and antidepressant medication use, these covariates selected based on
review of the literature for relevant characteristics.
Log-binomial regression were used to evaluate factors associated with
change in PHQ-2-defined depression-screen during follow-up. In these
analyses, those who changed from positive to negative depression-screen
were compared to those who screened positive for depression at both
timepoints, while those who changed from negative to positive depres-
sion-screen were compared to those who screened negative for depres-
sion at both timepoints. Multivariable models for predictors of change in
depression-screen were adjusted for age, P-MSSS, fatigue, antidepressant
medication use, and baseline continuous PHQ-2 score.
All multivariable models were done using complete-case analysis;
that is, constrained to those who had data on all model covariates.
STATA/SE 15.0 (StataCorp, College Park, USA) was used for data
analysis.
4. Results
At baseline, 2503 participants initiated the questionnaire, of whom
2224 (88.9%) completed the PHQ-2 instrument. At 2.5-year review,
1441 participants (57.6% retention rate) initiated the questionnaire, of
whom 1264 (90.2%) completed the PHQ-9 instrument.
As described elsewhere (Hadgkiss et al., 2013; Weiland et al., 2018), the
cohort was majority female at both timepoints, of mean age in the mid-40s
and the mean BMI was in the overweight range. Roughly three-quarters of
participants reported relapsing-remitting MS (RRMS), median duration from
diagnosis of 6 years, and a low level of disability, though clinically sig-
nificant fatigue was present in approximately two-thirds of participants at
both timepoints. At baseline, immunomodulatory medication use was re-
ported in 46.7%, decreasing to 42.0% at follow-up. Prescription anti-
depressant use was reported by roughly 17% of participants at baseline and
follow-up. Other cohort characteristics are shown in Supplemental Table 1.
4.1. Prevalence & determinants of positive depression-screen
At 2.5-year review, the prevalence of PHQ-2 positive depression-screen
was 14.5%, significantly decreased from that seen at baseline (19.1%,
p=0.002). However, the prevalence of PHQ-9 positive depression- screen at
2.5-year review was higher (21.7%). The kappa statistic for inter-rater
agreement was 62.4% (p< 0.001), observed agreement significantly greater
than expected by chance (88.8% vs 70.3%). The sensitivity and specificity of
the PHQ-2 as compared to the PHQ-9 were 56.9% and 97.7%, respectively.
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As in Table 1, being married/partnered was associated with sig-
nificantly lower frequency of PHQ-2 and PHQ-9 positive depression-
screen, persisting on adjustment. Analogous results were seen for social
network number, a larger network associated with significantly smaller
proportions with depression. Being employed and having completed
more education were associated with lower frequencies of positive
depression-screen, and PRSES was inversely associated with depression,
though adjustment attenuated all these associations. Neither age or sex
was significantly associated with positive depression-screen, though
older age was inversely associated after adjustment.
Being overweight/obese at follow-up and greater comorbidity number
were associated with a higher frequency of positive depression-screen,
persisting on adjustment (Table 3). Antidepressant and anxiolytic medi-
cation use were associated with positive depression-screen, but the latter
association was markedly reduced on adjustment for antidepressant use.
Compared to relapsing-remitting cases, the frequency of positive
depression-screen was significantly higher among progressive cases,
though these associations attenuated on adjustment for disability and
fatigue. Greater relapse number in the preceding year was positively
associated with depression-screen by both instruments, though only the
PHQ-9 association persisted on adjustment. Disability and fatigue were
both strongly positively associated with depression-screen by both
scales, each largely resilient to mutual adjustment. Immunomodulatory
medication use was not significantly associated with positive depres-
sion-screen, though use of interferon-β medication was positively as-
sociated with depression, reaching significance for PHQ-9.
4.2. Determinants of PHQ-9 depression severity
The inverse association seen between age and positive depression-
screen was only evident for major depression (Table 3). The protective
association of being married/partnered was solely evident for mod-
erate/severe-major depression, whereas the benefits of a larger social
network were seen for all grades of major depression. Employment was
associated with all grades of depression, whereas the inverse associa-
tion of education was only significant for moderate/severe-major de-
pression. The positive association of PRSES was solely evident for major
depression, while the inverse association of PRSES was present at all
levels of depression.
The association of overweight/obese BMI with positive depression-
screen was most evident for major depression (Table 4). Greater co-
morbidity number and antidepressant medication use were significantly
associated with all grades of depression symptoms but was of greatest
magnitude for major depression.
MS type was not significantly associated with depression grade.
Greater disability was associated with major depression, albeit with
mixed dose-dependency. Fatigue, however, showed pronounced dose-
dependency, with 31.7-times greater frequency of moderate/severe-
major depression among those with fatigue. Disease duration, while not
significantly associated with PHQ-9 depression overall, was strongly
and significantly associated with moderate/major severe depression.
Immunomodulatory medication use was not associated with depression
symptoms, though interferon-β was associated with moderate/severe-
major depression.
4.3. Determinants of change in PHQ-2 between reviews
As in Table 5, neither sex nor age were significantly associated with
change in depression. Those who were married/partnered at baseline
were significantly less likely to become depressed after adjustment, but
there was no impact of marital status on recovery from depression.
Those with a larger social support network at baseline were less likely
Table 1
Associations of demographic covariates with positive depression-screen at 2.5-year follow-up, as measured by PHQ-2 & PHQ-9.
n/N with PHQ-2 > 2 (%) Univariable Adjusteda N with PHQ-9>9 (%) Univariable Adjusteda
Age
18–38
>38–46
>46–54
>54–87
Trend:
32/232 (13.8%)
43/319 (13.5%)
59/343 (17.2%)
56/415 (13.5%)
1.00 [Reference]
0.98 (0.64, 1.50)
1.25 (0.84, 1.86)
0.98 (0.65, 1.47)
p=0.86
1.00 [Reference]
0.82 (0.55, 1.23)
0.83 (0.56, 1.22)
0.67 (0.45, 1.00)
p=0.055
47/226 (20.8%)
64/310 (20.7%)
81/332 (24.4%)
82/396 (20.7%)
1.00 [Reference]
0.99 (0.71, 1.39)
1.17 (0.85, 1.61)
1.00 (0.72, 1.37)
p= 0.83
1.00 [Reference]
0.82 (0.61, 1.12)
0.78 (0.58, 1.05)
0.65 (0.48, 0.88)
p=0.005
Marital status
Not married/partnered
Married/partnered
59/305 (19.3%)
128/992 (12.9%)
1.00 [Reference]
0.67 (0.50, 0.88)
p=0.005
1.00 [Reference]
0.71 (0.54, 0.93)
p=0.014
80/293 (27.3%)
190/960 (19.8%)
1.00 [Reference]
0.73 (0.58, 0.91)
p=0.005
1.00 [Reference]
0.79 (0.64, 0.98)
p=0.033
Number of people in support network
0
1
2 – 5
>5
Trend:
13/43 (30.2%)
56/269 (20.8%)
95/784 (12.1%)
12/155 (7.7%)
1.00 [Reference]
0.69 (0.41, 1.15)
0.40 (0.25, 0.66)
0.26 (0.13, 0.52)
p < 0.001
1.00 [Reference]
0.84 (0.53, 1.31)
0.53 (0.35, 0.82)
0.37 (0.19, 0.73)
p < 0.001
18/40 (45.0%)
81/260 (31.2%)
141/758 (18.6%)
18/151 (11.9%)
1.00 [Reference]
0.69 (0.47, 1.02)
0.41 (0.29, 0.60)
0.27 (0.15, 0.46)
p < 0.001
1.00 [Reference]
0.82 (0.57, 1.18)
0.50 (0.36, 0.72)
0.38 (0.22, 0.64)
p < 0.001
Employment status
Not employed
Employed
106/595 (17.8%)
84/706 (11.9%)
1.00 [Reference]
0.67 (0.51, 0.87)
p=0.003
1.00 [Reference]
1.01 (0.77, 1.33)
p=0.96
163/568 (28.7%)
111/688 (16.1%)
1.00 [Reference]
0.56 (0.45, 0.70)
p < 0.001
1.00 [Reference]
0.78 (0.64, 0.98)
p=0.036
Level of education completed
None/primary/secondary
Vocational school
Bachelor's degree
Post-graduate study
Trend:
51/257 (19.8%)
35/197 (17.8%)
70/492 (14.2%)
33/358 (9.2%)
1.00 [Reference]
0.90 (0.61, 1.32)
0.72 (0.52, 1.00)
0.47 (0.31, 0.70)
p < 0.001
1.00 [Reference]
0.95 (0.65, 1.39)
0.93 (0.68, 1.28)
0.65 (0.44, 0.96)
p=0.038
76/249 (30.5%)
49/191 (25.7%)
92/472 (19.5%)
55/347 (15.9%)
1.00 [Reference]
0.84 (0.62, 1.14)
0.64 (0.49, 0.83)
0.52 (0.38, 0.71)
p < 0.001
1.00 [Reference]
0.88 (0.66, 1.18)
0.80 (0.62, 1.03)
0.67 (0.50, 0.89)
p=0.004
Perceived socioeconomic status relative to peers
Lower
Same
Higher
Trend:
66/255 (25.9%)
65/411 (15.8%)
59/636 (9.3%)
1.64 (1.21, 2.22)
1.00 [Reference]
0.59 (0.42, 0.82)
p < 0.001
1.20 (0.89, 1.62)
1.00 [Reference]
0.73 (0.53, 1.01)
p=0.002
101/247 (40.9%)
83/391 (21.2%)
88/619 (14.2%)
1.93 (1.51, 2.46)
1.00 [Reference]
0.67 (0.51, 0.88)
p < 0.001
1.50 (1.18, 1.90)
1.00 [Reference]
0.83 (0.64, 1.08)
p < 0.001
Analyses by log-binomial regression, estimating a prevalence ratio (PR) (95% CI).
Figures in boldface denote statistical significance (p < 0.05). Figures in italics are p-values.
Abbreviations: FSS= Fatigue Severity Scale; PHQ=Patient Health Questionnaire; P-MSSS=Patient Determined Multiple Sclerosis Severity Score.
a Adjusted models adjusted for age, P-MSSS, FSS, and use of prescription antidepressant medication.
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to become depressed, becoming stronger on adjustment. Baseline em-
ployment was associated with significantly lower risk of becoming de-
pressed; however, on adjustment, these associations were abrogated.
Participants who completed postgraduate education were significantly
more likely to recover from depression between reviews, persisting on
adjustment, whereas there was a reciprocal protective association of
greater education against becoming depressed. While higher PRSES was
not associated with change in depression state, those of lower PRSES
had a significantly higher frequency of becoming depressed, persisting
on adjustment.
Baseline overweight/obese BMI was associated with a significantly
greater risk of becoming depressed at follow-up, though attenuating on
adjustment (Table 6). Greater comorbidity number was associated with
a significantly greater risk of becoming depressed (ptrend < 0.001),
though this association became less dose-dependent and nonsignificant
on adjustment. Baseline antidepressant use was associated with a 2.2-
fold increased risk of becoming depressed, attenuating slightly on ad-
justment. Similar associations were seen for anxiolytic medication, but
these were largely abrogated on adjustment for antidepressant use.
After adjustment, PRMS cases were 1.6-times more likely to lose
depression, compared to benign/RRMS cases, while SPMS cases were
over 2-fold more likely to gain depression. While relapse number was
not associated with change in depression-state, a greater level of dis-
ability was associated with a significantly greater risk of becoming
depressed, though this association was largely abrogated on adjustment
for fatigue. Fatigue, on the other hand, was associated with 3-fold
Table 2
Associations of clinical covariates with positive depression-screen at 2.5-year follow-up, as measured by PHQ-2 & PHQ-9.
n/N with PHQ-2 > 2(%) Univariable Adjusteda N with PHQ-9 > 9(%) Univariable Adjusteda
BMI
Underweight/normal
Overweight/obese
85/790 (10.8%)
15/517 (20.3%)
1.00 [Reference]
1.89 (1.45, 2.46)
p < 0.001
1.00 [Reference]
1.31 (1.01, 1.70)
p=0.042
117/766 (15.3%)
157/496 (31.7%)
1.00 [Reference]
2.07 (1.68, 2.56)
p < 0.001
1.00 [Reference]
1.56 (1.27, 1.92)
p < 0.001
Number of comorbidities as defined by SCQ
0
1
2
≥3
Trend:
48/631 (7.6%)
50/361 (13.9%)
40/181 (22.1%
52/136 (38.2%)
1.00 [Reference]
1.82 (1.25, 2.65)
2.91 (1.98, 4.27)
5.03 (3.56, 7.10)
p < 0.001
1.00 [Reference]
1.46 (1.00, 2.14)
1.89 (1.26, 2.83)
3.02 (2.06, 4.44)
p < 0.001
68/618 (11.0%)
79/344 (23.0%)
57/174 (32.8%)
70/128 (54.7%)
1.00 [Reference]
2.09 (1.55, 2.81)
2.98 (2.19, 4.06)
4.97 (3.78, 6.54)
p < 0.001
1.00 [Reference]
1.74 (1.30, 2.34)
2.11 (1.53, 2.90)
3.09 (2.28, 4.19)
p < 0.001
Taking prescription antidepressant medication?
No
Yes
114/1060 (10.8%)
76/249 (30.5%)
1.00 [Reference]
2.84 (2.20, 3.66)
p < 0.001
1.00 [Reference]
2.11 (1.63, 2.73)
p < 0.001
167/1031 (16.2%)
107/233 (45.9%)
1.00 [Reference]
2.84 (2.33, 3.45)
p < 0.001
1.00 [Reference]
2.21 (1.81, 2.69)
p < 0.001
Taking prescription anxiolytic medication?
No
Yes
156/1,1904 (13.1%)
34/115 (29.6%)
1.00 [Reference]
2.26 (1.65, 3.11)
p < 0.001
1.00 [Reference]
1.28 (0.93, 1.77)
p= 0.13
226/1157 (19.5%)
48/107 (44.9%)
1.00 [Reference]
2.30 (1.81, 2.92)
p<0.001
1.00 [Reference]
1.32 (1.03, 1.69)
p=0.030
Type of MS at completion of survey
Benign/RRMS
PPMS
SPMS
PRMS
Unsure/other
102/853 (12.0%)
40/13 (20.7%)
22/105 (21.0%)
3/22 (13.6%)
23/132 (17.4%)
1.00 [Reference]
1.73 (1.25, 2.41)
1.75 (1.16, 2.65)
1.14 (0.39, 3.32)
1.46 (0.96, 2.20)
1.00 [Reference]
1.23 (0.85, 1.76)
1.32 (0.84, 2.07)
0.67 (0.23, 1.98)
1.31 (0.88, 1.95)
157/826 (19.0%)
45/186 (24.2%)
32/102 (31.4%)
8/22 36.4%)
31/125 (24.8%)
1.00 [Reference]
1.27 (0.95, 1.70)
1.65 (1.20, 2.27)
1.91 (1.08, 3.39)
1.31 (0.93, 1.83)
1.00 [Reference]
0.88 (0.64, 1.19)
1.23 (0.86, 1.76)
1.16 (0.64, 2.08)
1.15 (0.83, 1.60)
Number of doctor-diagnosed relapses in preceding 12 months
0
1
2
≥3
Trend:
132/985 (13.4%)
37/214 (17.3%)
7/44 (15.9%)
9/24 (37.5%)
1.00 [Reference]
1.29 (0.92, 1.80)
1.19 (0.59, 2.39)
2.80 (1.63, 4.81)
p=0.002
1.00 [Reference]
0.89 (0.63, 1.26)
0.61 (0.31, 1.22)
1.18 (0.68, 2.05)
p= 0.58
179/960 (18.7%)
60/203 (29.6%)
13/40 (32.5%)
13/22 (59.1%)
1.00 [Reference]
1.59 (1.23, 2.04)
1.74 (1.09, 2.78)
3.17 (2.18, 4.60)
p<0.001
1.00 [Reference]
1.20 (0.94, 1.53)
1.13 (0.73, 1.75)
1.61 (1.08, 2.39)
p=0.023
P-MSSS disability
Mild disability (0–3)
Moderate disability (4–6)
Severe disability (>6)
Trend:
25/398 (6.3%)
58/390 (14.9%)
104/506 (20.6%)
1.00 [Reference]
2.37 (1.51, 3.71)
3.27 (2.16, 4.96)
p<0.001
1.00 [Reference]
1.60 (1.02, 2.49)
1.93 (1.26, 2.96)
p=0.002
46/385 (12.0%)
73/378 (19.3%)
147/487 (30.2%)
1.00 [Reference]
1.62 (1.15, 2.27)
2.53 (1.87, 3.42)
p<0.001
1.00 [Reference]
1.12 (0.81, 1.54)
1.54 (1.15, 2.08)
p=0.001
Fatigue, as defined by FSS>35
No fatigue
Fatigue
12/474 (2.5%)
173/786 (22.0%)
1.00 [Reference]
8.69 (4.90, 15.44)
p<0.001
1.00 [Reference]
6.37 (3.48, 11.65)
p<0.001
28/464 (6.0%)
242/757 (32.0%)
1.00 [Reference]
5.30 (3.65, 7.70)
p<0.001
1.00 [Reference]
4.20 (2.83, 6.24)
p<0.001
Disease duration from symptom onset, years
2.91–8.19
>8.19–14.23
>14.23–23.20
>23.20–56.14
Trend:
38/327 (11.6%)
47/324 (14.5%)
52/328 (15.9%)
53/327 (16.2%)
1.00 [Reference]
1.25 (0.84, 1.86)
1.36 (0.92, 2.01)
1.40 (0.95, 2.06)
p= 0.079
1.00 [Reference]
1.16 (0.80, 1.69)
1.13 (0.76, 1.67)
1.08 (0.71, 1.65)
p= 0.75
50/318 (15.7%)
66/312 (21.2%)
75/319 (23.5%)
81/312 (26.0%)
1.00 [Reference]
1.35 (0.97, 1.88)
1.50 (1.08, 2.06)
1.65 (1.20, 2.27)
p=0.001
1.00 [Reference]
1.23 (0.90, 1.67)
1.29 (0.93, 1.78)
1.30 (0.92, 1.84)
p=0.16
Taking any of the 11 specified immunomodulatoryb medications?
None
Interferon-β
Other
103/723 (14.3%)
25/121 (20.7%)
62/465 (13.3%)
1.00 [Reference]
1.45 (0.98, 2.15)
0.94 (0.70, 1.25)
1.00 [Reference]
1.21 (0.83, 1.76)
0.75 (0.56, 1.00)
138/698 (19.8%)
36/119 (30.3%)
100/447 (22.4%)
1.00 [Reference]
1.53 (1.12, 2.09)
1.13 (0.90, 1.42)
1.00 [Reference]
1.34 (1.03, 1.75)
0.91 (0.73, 1.14)
Analyses by log-binomial regression, estimating a prevalence ratio (PR) (95% CI).
Figures in boldface denote statistical significance (p < 0.05). Figures in italics are p-values.
Abbreviations: BMI=Body mass index; FSS= Fatigue Severity Scale; PHQ=Patient Health Questionnaire; P-MSSS=Patient Determined Multiple Sclerosis
Severity Score; PPMS=Primary progressive multiple sclerosis; PRMS=Progressive-relapsing multiple sclerosis; RRMS=Relapsing-remitting multiple sclerosis;
SCQ= Self-administered Comorbidity Questionnaire; SPMS=Secondary progressive multiple sclerosis.
a Adjusted models adjusted for age, P-MSSS, FSS, and use of prescription antidepressant medication.
b Immunomodulatory medications queried include interferon-β-based medication, glatiramer acetate, alemtuzumab, cladribine, daclizumab, dimethyl fumarate,
fingolimod, laquinimod, rituximab, teriflunomide, and natalizumab.
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greater risk of becoming depressed, largely robust to adjustment for
disability. No consistent or material associations were seen between
immunomodulatory medication use and subsequent change in depres-
sion-state.
5. Discussion
We found PHQ-2 positive depression-screen prevalence fell sig-
nificantly during follow-up, from 19.1% to 14.5%, though this may be
an underestimate since the more comprehensive PHQ-9 found an esti-
mated depression-screen prevalence of 21.7%. These results are in
keeping with the literature, a systematic review finding an MS PHQ-9
depression-screen prevalence of 23.9% in MS patients
(Boeschoten et al., 2017). We replicated our previous findings
(Taylor et al., 2014), showing that BMI, comorbidity number, fatigue,
and disability were significantly predictive of positive depression-
screen, while marital status, employment, and education were nega-
tively associated with risk of depression-screen. Also, many of these
factors were significantly predictive of change in depression state.
Depression is a common comorbidity in MS, affecting between one-
quarter to one-third of patients (Boeschoten et al., 2017). The me-
chanisms underlying depression in MS are uncertain, though unlike in
the general population, where depression is largely of genetic aetiology,
in MS it may reflect common pathological processes (Sadovnick et al.,
1996). Given the interrelationship of the immune and nervous systems
at the hypothalamus-pituitary-adrenal axis, depression symptoms may
be due to the same inflammatory processes driving MS symptoms
(Solaro et al., 2018). By identifying the determinants of depression in
MS, we might predict and potentially reduce depression among people
with MS.
Progressive MS type, relapse number, disability and fatigue were all
associated with increased risk of positive depression-screen, though of
these, only fatigue persisted on adjustment. These results suggest that
fatigue, not disability, is the driver of depression. Disability and fati-
gue's strong associations with depression have been demonstrated both
in early and established MS (Berzins et al., 2017; Brown et al., 2009;
Koch et al., 2009; Simpson et al., 2016; Wood et al., 2012). Greeke and
colleagues found that persons with significant fatigue were at especial
risk of developing depression (Greeke et al., 2017), while Gunzler and
colleagues found that baseline disability strongly predicted depression
trajectory among 3507 MS patients (Gunzler et al., 2016). Moreover,
there is some indication that treating depression may impact perceived
fatigue (Mohr et al., 2003), potentially facilitating a feedback cycle to
improve mental quality of life.
Overweight/obese BMI was significantly associated with increased
risk of newly positive depression-screen; however, these associations
became non-significant on adjustment. This suggests that despite
known inflammatory effects of adiposity (Capuron et al., 2017), its
impact on depression was not independent of clinical factors. Co-
morbidity number showed a dose-dependent association with increased
risk of newly positive depression-screen. Comorbidities have been as-
sociated with clinical outcomes in MS (Marrie and Horwitz, 2010), and
while some are potentially due to common inflammatory antecedents
(Rossi et al., 2017), others like depression could be attributable both to
common pathophysiological processes, and to MS symptoms and other
comorbidities. Thus, it is not surprising that comorbidity number was
positively associated with depression, even after adjustment for dis-
ability and fatigue. The positive associations seen for antidepressant
and anxiolytic medication and depression-screen are most likely reverse
causal in nature, whereby those with depression are more likely to be
taking these medications, rather than a deleterious effect of the medi-
cations on mood.
Beyond clinical features, marital status, employment, socio-
economic status, and education were associated with depression state.
Being employed or partnered predicted a significantly reduced risk of
newly positive depression-screen. However, while marital status'sTa
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association persisted on adjustment, that of employment was elimi-
nated. Notably, while a higher PRSES was not significantly associated
with change in depression, lower PRSES was robustly associated with
significantly greater risk of becoming depressed. Given the subjective
nature of PRSES and given that employment was not independently
associated with change in depression, it is potentially more the per-
ception rather than status itself which affected depression. The impacts
of demographic characteristics on depression have been shown pre-
viously. In a study of 451 US veterans, Williams and colleagues found
unemployment, lower income and lack of partner were positively as-
sociated with depression (Williams et al., 2005). Likewise, a cohort
study of 236 patients followed for five years in early MS found that
depression was significantly more common among unemployed parti-
cipants (Simpson et al., 2016). Given the potential for positive feed-
back, whereby unemployment leads to greater depression (Maier et al.,
2016), this could exacerbate symptoms, leading to worse quality of life.
5.1. Strengths and limitations
A major strength of our sample was the breadth of data on lifestyle
and clinical factors. Our data are self-reported so the potential for recall
bias exists. We recruited and retained a large sample size, including
people with all types of MS from geographically diverse backgrounds.
Validated tools were used wherever possible and potential confounders
were adjusted for. Not all participants responded to every question and
thus, there was some missing data. Accordingly, all multivariate models
were complete-case analysis, restricted to those with data on all model
parameters. Reverse causality cannot be excluded from some associa-
tions. However, the biological plausibility, dose-dependency and con-
sistency with existing literature support the veracity of these findings.
Potentially, severely depressed people might not participate in this study
and thus, our assessment of the frequency and determinants of severe de-
pression could be affected. Our sample may be biased due to participants
being recruited via online platforms, potentially recruiting a healthier co-
hort. In addition, there was appreciable attrition between baseline and
follow-up reviews, with a retention rate of 56.8%. While there was some
evidence that those retained in the study engaged in less unhealthy beha-
viours like smoking, other behaviours like alcohol, physical activity and
supplement use were not materially different, and clinical characteristics
like disability or fatigue were comparable. However, significantly more
people with depression risk at baseline were lost to follow-up, suggesting
that our estimates of depression prevalence at follow-up may underestimate
the true prevalence, and that associations with depression state may also be
affected. This may also account for the drop in depression during follow-up.
Our lack of data on the PHQ-9 at baseline does preclude the as-
sessment of change in this parameter. While we can calculate PHQ-2 at
both timepoints and thus assess change in this, the absence of data on
the more comprehensive PHQ-9 at baseline is a limitation.
Table 5
Demographic predictors of change in PHQ-2 depression state between baseline and 2.5-year follow-up.
N with positive
depression-
screen at both
baseline &
follow-up (row
%)
N with positive
depression-
screen at
baseline, not at
follow-up (row
%)
RR loss of
positive
depression-screen
vs positive
depression-screen
at both
timepoints
aRRa loss of
positive
depression-screen
vs positive
depression-screen
at both
timepoints
N with negative
depression-
screen at both
baseline &
follow-up (row
%)
N with negative
depression-screen
at baseline but
with positive
depression-screen
at follow-up (row
%)
RR gain of
positive
depression-screen
vs negative
depression-screen
at both
timepoints
aRRa gain of
positive
depression-screen
vs negative
depression-screen
at both
timepoints
18 – 38
>38 – 46
>46 – 54
>54 – 87
Trend:
9 (29.0%)
16 (44.4%)
25 (53.2%)
21 (40.4%)
22 (71.0%)
20 (55.6%)
22 (46.8%)
31 (59.6%)
1.00 [Reference]
0.75 (0.52, 1.08)
0.66 (0.45, 0.96)
0.81 (0.59, 1.11)
p= 0.25
1.00 [Reference]
0.83 (0.58, 1.19)
0.76 (0.53, 1.08)
0.85 (0.59, 1.21)
p= 0.26
170 (90.4%)
243 (90.3%)
245 (90.1%)
317 (90.8%)
18 (9.6%)
26 (9.7%)
27 (9.9%)
32 (9.2%)
1.00 [Reference]
0.97 (0.55, 1.71)
1.11 (0.64, 1.94)
1.05 (0.61, 1.80)
p= 0.75
1.00 [Reference]
1.16 (0.70, 1.91)
0.85 (0.50, 1.45)
0.81 (0.46, 1.44)
p= 0.25
Married/partnered at baseline?
No
Yes
24 (45.3%)
45 (40.5%)
29 (54.7%)
66 (59.5%)
1.00 [Reference]
1.09 (0.82, 1.45)
p= 0.57
1.00 [Reference]
1.10 (0.82, 1.47)
p= 0.55
200 (87.7%)
766 (91.4%)
28 (12.3%)
72 (8.6%)
1.00 [Reference]
0.74 (0.49, 1.11)
p= 0.14
1.00 [Reference]
0.62 (0.41, 0.94)
p=0.024
Number of people in support network at baseline
0
1
2 – 5
>5
Trend:
6 (60.0%)
20 (40.0%)
35 (39.3%)
10 (62.5%)
4 (40.0%)
30 (60.0%)
54 (60.7%)
6 (37.5%)
1.00 [Reference]
1.44 (0.64, 3.27)
1.43 (0.64, 3.20)
0.86 (0.32, 2.34)
p= 0.61
1.00 [Reference]
1.65 (0.62, 4.37)
1.68 (0.64, 4.38)
1.14 (0.37, 3.46)
p= 0.96
33 (84.6%)
178 (90.4%)
607 (90.3%)
151 (93.2%)
6 (15.4%)
19 (9.6%)
65 (9.7%)
11 (6.8%)
1.00 [Reference]
0.67 (0.29, 1.55)
0.68 (0.32, 1.44)
0.55 (0.22, 1.38)
p= 0.33
1.00 [Reference]
0.54 (0.25, 1.19)
0.45 (0.23, 0.89)
0.42 (0.18, 0.95)
p= 0.11
Employment status at baseline
Not employed
Employed
33 (38.4%)
37 (46.8%)
53 (61.6%)
42 (53.2%)
1.00 [Reference]
0.87 (0.67, 1.13)
p= 0.30
1.00 [Reference]
0.87 (0.65, 1.16)
p= 0.33
380 (88.0%)
594 (92.1%)
52 (12.0%)
51 (7.9%)
1.00 [Reference]
0.69 (0.48, 0.99)
p=0.045
1.00 [Reference]
0.93 (0.62, 1.38)
p= 0.71
Level of education completed
None/primary/
secondary
Vocational
school
Bachelor's
degree
Post-
graduate study
Trend:
21 (50.0%)
15 (44.1%)
30 (49.2%)
5 (17.9%)
21 (50.0%)
19 (55.9%)
31 (50.8%)
23 (82.1%)
1.00 [Reference]
1.06 (0.69, 1.62)
0.99 (0.68, 1.46)
1.58 (1.12, 2.23)
p= 0.057
1.00 [Reference]
1.27 (0.81, 1.98)
1.04 (0.70, 1.56)
1.74 (1.20, 2.53)
p= 0.074
168 (87.1%)
135 (88.2%)
379 (91.6%)
290 (92.4%)
25 (13.0%)
18 (11.8%)
35 (8.5%)
24 (7.6%)
1.00 [Reference]
0.92 (0.52, 1.63)
0.66 (0.41, 1.07)
0.57 (0.34, 0.97)
p=0.018
1.00 [Reference]
1.13 (0.63, 2.03)
0.79 (0.49, 1.28)
0.70 (0.40, 1.22)
p= 0.11
Perceived socioeconomic status relative to peers
Lower
Same
Higher
Trend:
26 (44.8%)
27 (43.6%)
18 (39.1%)
32 (55.2%)
35 (56.5%)
28 (60.9%)
1.00 (0.73, 1.38)
1.00 [Reference]
1.08 (0.79, 1.48)
p= 0.65
0.99 (0.72, 1.38)
1.00 [Reference]
1.06 (0.76, 1.48)
p= 0.67
141 (80.6%)
300 (90.4%)
527 (93.4%)
34 (19.4%)
32 (9.6%)
37 (6.6%)
1.87 (1.20, 2.90)
1.00 [Reference]
0.72 (0.46, 1.13)
p < 0.001
1.61 (1.02, 2.53)
1.00 [Reference]
0.78 (0.49, 1.24)
p=0.005
Analyses by log-binomial regression, estimating a risk ratio (RR) (95% CI).
Figures in boldface denote statistical significance (p < 0.05). Figures in italics are p-values.
Abbreviations: FSS= Fatigue Severity Scale; PHQ=Patient Health Questionnaire; P-MSSS=Patient Determined Multiple Sclerosis Severity Score.
a Adjusted models adjusted for age, baseline P-MSSS, baseline FSS, baseline use of antidepressant, and baseline PHQ-2 score.
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Table 6
Clinical predictors of change in PHQ-2 depression state between baseline and 2.5-year follow-up.
N with positive
depression-
screen at both
baseline &
follow-up (row
%)
N with positive
depression-
screen at
baseline, not at
follow-up (row
%)
RR loss of
positive
depression-screen
vs positive
depression-screen
at both
timepoints
aRRa loss of
positive
depression-screen
vs positive
depression-screen
at both
timepoints
N with negative
depression-
screen at both
baseline &
follow-up (row
%)
N with negative
depression-screen
at baseline but
with positive
depression-screen
at follow-up (row
%)
RR gain of
positive
depression-screen
vs negative
depression-screen
at both
timepoints
aRRa gain of
positive
depression-screen
vs negative
depression-screen
at both timepoints
Overweight/obese BMI at baseline
No
Yes
32 (42.1%)
39 (43.3%)
44 (57.9%)
51 (56.7%)
1.00 [Reference]
0.98 (0.76, 1.28)
p= 0.91
1.00 [Reference]
1.00 (0.76, 1.33)
p= 0.99
651 (92.3%)
322 (86.8%)
54 (7.7%)
49 (13.2%)
1.00 [Reference]
1.65 (1.15, 2.36)
p=0.007
1.00 [Reference]
1.42 (0.98, 2.06)
p= 0.061
Number of comorbidities as defined by SCQ at baseline
0
1
2
≥3
Trend:
9 (42.9%)
12 (30.8%)
18 (41.9%)
32 (50.8%)
12 (57.1%)
27 (69.2%)
25 (58.1%)
31 (49.2%)
1.00 [Reference]
1.27 (0.83, 1.94)
1.07 (0.68, 1.68)
0.94 (0.60, 1.49)
p= 0.32
1.00 [Reference]
1.34 (0.89, 2.04)
1.05 (0.65, 1.68)
1.00 (0.62, 1.60)
p= 0.38
406 (94.4%)
295 (91.6%)
169 (84.1%)
105 (84.0%)
24 (5.6%)
27 (8.4%)
32 (15.9%)
20 (16.0%)
1.00 [Reference]
1.42 (0.84, 2.40)
2.31 (1.38, 3.87)
2.29 (1.32, 3.99)
p < 0.001
1.00 [Reference]
1.23 (0.71, 2.13)
1.77 (1.03, 3.04)
1.47 (0.77, 2.82)
p= 0.11
Taking prescription antidepressant medication at baseline?
No
Yes
44 (42.3%)
27 (43.6%)
60 (57.7%)
35 (56.5%)
1.00 [Reference]
1.01 (0.77, 1.32)
p= 0.97
1.00 [Reference]
0.93 (0.70, 1.25)
p= 0.64
853 (92.2%)
122 (79.7%)
72 (7.8%)
31 (20.3%)
1.00 [Reference]
2.21 (1.50, 3.28)
p < 0.001
1.00 [Reference]
2.00 (1.35, 2.96)
p=0.001
Taking prescription anxiolytic medication at baseline?
No
Yes
60 (42.3%)
11 (45.8%)
82 (57.8%)
13 (54.2%)
1.00 [Reference]
0.96 (0.64, 1.44)
p= 0.84
1.00 [Reference]
0.86 (0.52, 1.40)
p= 0.54
912 (91.5%)
63 (77.8%)
85 (8.5%)
18 (22.2%)
1.00 [Reference]
2.21 (1.43, 3.42)
p < 0.001
1.00 [Reference]
1.52 (0.90, 2.58)
p= 0.12
Type of MS at completion of survey
Benign/RRMS
PPMS
SPMS
PRMS
Unsure/
other
41 (40.6%)
19 (61.3%)
4 (25.0%)
1 (16.7%)
6 (50.0%)
60 (59.4%)
12 (38.7%)
12 (75.0%)
5 (83.3%)
6 (50.0%)
1.00 [Refeence]
0.65 (0.41, 1.04)
1.19 (0.85, 1.64)
1.46 (0.97, 2.19)
0.92 (0.52, 1.62)
1.00 [Reference]
0.61 (0.36, 1.05)
1.12 (0.76,1.66)
1.60 (1.00, 2.56)
0.92 (0.52, 1.63)
660 (92.8%)
135 (88.2%)
66 (80.5%)
13 (86.7%)
97 (85.8%)
51 (7.2%)
18 (11.8%)
16 (19.5%)
2 (13.3%)
16 (14.2%)
1.00 [Reference]
1.44 (0.86, 2.41)
2.55 (1.54, 4.22)
1.93 (0.47, 7.88)
1.83 (1.09, 3.06)
1.00 [Reference]
1.05 (0.55, 1.99)
2.06 (1.10, 3.86)
1.39 (0.34, 5.67)
1.56 (0.86, 2.83)
Number of doctor-diagnosed relapses in preceding 12 months
0
1
2
≥3
Trend:
45 (41.7%)
17 (47.2%)
3 (33.3%)
3 (50.0%)
63 (58.3%)
19 (52.8%)
6 (66.7%)
3 (50.0%)
1.00 [Reference]
0.90 (0.64, 1.27)
1.23 (0.76, 2.00)
0.85 (0.37, 1.96)
p= 0.86
1.00 [Reference]
0.88 (0.61, 1.27)
1.36 (0.87, 2.12)
0.87 (0.39, 1.97)
p= 0.95
754 (91.0%)
148 (89.2%)
28 (90.3%)
12 (70.6%)
75 (9.1%)
18 (10.8%)
3 (9.7%)
5 (29.4%)
1.00 [Reference]
1.15 (0.71, 1.88)
0.96 (0.32, 2.83)
2.93 (1.38, 6.21)
p= 0.074
1.00 [Reference]
1.09 (0.65, 1.82)
0.82 (0.26, 2.63)
2.09 (0.85, 5.12)
p= 0.39
P-MSSS disability at baseline
Mild disability
(0–3)
Moderate
disability (4–6)
Severe
disability (>6)
Trend:
12 (38.7%)
23 (46.9%)
35 (41.2%)
19 (61.3%)
26 (53.1%)
50 (58.8%)
1.00 [Reference]
0.82 (0.57, 1.27)
0.97 (0.69, 1.37)
p= 0.93
1.00 [Reference]
0.88 (0.57, 1.34)
1.02 (0.70, 1.48)
p= 0.69
370 (93.9%)
283 (93.4%)
313 (84.6%)
24 (6.1%)
20 (6.6%)
57 (15.4%)
1.00 [Reference]
1.04 (0.59, 1.83)
2.14 (1.36, 3.37)
p=0.001
1.00 [Reference]
0.76 (0.42, 1.37)
1.41 (0.86, 2.32)
p= 0.11
Fatigue, as defined by FSS>35 at baseline
No fatigue
Fatigue
5 (38.5%)
62 (43.1%)
8 (61.5%)
82 (56.9%)
1.00 [Reference]
0.90 (0.58, 1.42)
p= 0.66
1.00 [Reference]
0.82 (0.52, 1.30)
p= 0.40
423 (96.6%)
513 (86.2%)
15 (3.4%)
82 (13.8%)
1.00 [Reference]
3.28 (1.89, 5.72)
p < 0.001
1.00 [Reference]
2.91 (1.59, 5.36)
p=0.001
Disease duration from symptom onset, years
2.91 – 8.19
>8.19 –
14.23
>14.23 –
23.20
>23.20 –
56.14
Trend:
13 (41.9%)
21 (48.8%)
14 (36.8%)
23 (42.6%)
18 (58.1%)
22 (51.2%)
24 (63.2%)
31 (57.4%)
1.00 [Reference]
0.86 (0.57, 1.30)
1.06 (0.72, 1.55)
0.97 (0.66, 1.42)
p= 0.83
1.00 [Reference]
1.00 (0.67, 1.51)
1.23 (0.81, 1.88)
1.21 (0.76, 1.93)
p= 0.43
259 (92.8%)
245 (91.8%)
239 (87.9%)
229 (89.1%)
20 (7.2%)
22 (8.2%)
33 (12.1%)
28 (10.9%)
1.00 [Reference]
1.21 (0.68, 2.14)
1.78 (1.06, 3.00)
1.60 (0.93, 2.75)
p=0.031
1.00 [Reference]
1.16 (0.64, 2.11)
1.62 (0.92, 2.84)
1.27 (0.68, 2.38)
p= 0.30
Taking any of the 11 specified immunomodulatory medications at baseline?b
None
Interferon-β
Other
31 (47.0%)
15 (33.3%)
25 (45.5%)
35 (53.0%)
30 (66.7%)
30 (54.6%)
1.00 [Reference]
1.25 (0.92, 1.70)
1.03 (0.74, 1.43)
1.00 [Reference]
1.30 (0.59, 1.77)
1.05 (0.74, 1.49)
525 (91.0%)
163 (89.6%)
287 (90.0%)
52 (9.0%)
19 (10.4%)
32 (10.0%)
1.00 [Reference]
1.15 (0.70, 1.89)
1.11 (0.74, 1.67)
1.00 [Reference]
1.16 (0.68, 1.97)
1.15 (0.76, 1.75)
Analyses by log-binomial regression, estimating a risk ratio (RR) (95% CI).
Figures in boldface denote statistical significance (p < 0.05). Figures in italics are p-values.
Abbreviations: BMI=Body mass index; FSS= Fatigue Severity Scale; PHQ=Patient Health Questionnaire; P-MSSS=Patient Determined Multiple Sclerosis
Severity Score; PPMS=Primary progressive multiple sclerosis; PRMS=Progressive-relapsing multiple sclerosis; RRMS=Relapsing-remitting multiple sclerosis;
SCQ= Self-administered Comorbidity Questionnaire; SPMS=Secondary progressive multiple sclerosis.
a Adjusted models adjusted for age, baseline P-MSSS, baseline FSS, baseline use of antidepressant, and baseline PHQ-2 score.
b Immunomodulatory medications queried include interferon-β-based medication, glatiramer acetate, alemtuzumab, cladribine, daclizumab, dimethyl fumarate,
fingolimod, laquinimod, rituximab, teriflunomide, and natalizumab.
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Another potential issue is the poor sensitivity – only 56.9% - of the
PHQ-2 against the PHQ-9, which was considered the referent standard
here given its greater comprehensiveness. The PHQ-2 and PHQ-9 had
good sensitivity (87% and 95%, respectively) in comparison to clini-
cally diagnosed depression (Kroenke et al., 2001; Lowe et al., 2005),
but the PHQ-2 has not been compared to the PHQ-9 as we have done
here. While both the PHQ-2 and PHQ-9 have fair sensitivity (84 and
80%, respectively) in comparison to a clinical diagnosis of major de-
pressive disorder (Gilbody et al., 2007), each measure has some
variability in its sensitivity in different patient populations. It may be
that the PHQ-2 was less sensitive in our sample than it might be in other
populations.
Since fatigue can be a symptom of depression and MS, another
limitation is that our measure of depression by the PHQ-9 which in-
cludes a question about energy, could realise higher PHQ-9 scores in
these individuals. It is encouraging, though, that we actually showed
even stronger associations between fatigue and PHQ-2 depression,
suggesting that while there is an element of fatigue in PHQ-9, the as-
sociations seen between fatigue and depression were not solely a
function of this.
6. Conclusions
In a large prospective cohort study of depressive symptoms in MS
patients, we found the frequency of positive depression-screen was
roughly 14–21%, depending which measure was used, but showed a
significant decline over 2.5-years follow-up. The principal factors as-
sociated with positive depression-screen and its change included mar-
ital status, employment, education, PRSES, BMI, disability, fatigue, and
antidepressant use. While some of these factors are not modifiable, our
results suggest that efforts to reduce fatigue in people with MS may
have a significant positive effect on depression in this population.
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